Literature DB >> 23686494

CD40 mediates downregulation of CD32B on specific memory B cell populations in rheumatoid arthritis.

Xiaoyu Zhang1, Erin Burch, Ling Cai, Edward So, Fleesie Hubbard, Eric L Matteson, Scott E Strome.   

Abstract

Altered B cell function is important in the pathogenesis of rheumatoid arthritis (RA). In this report, we show that patients with active RA have an increased frequency of CD32B low/neg cells in the CD27(+)IgD(-) memory B cell subset and that these changes are associated with phenotypic and functional B cell activation. Studies using PBMCs from healthy donors revealed that downregulation of CD32B on B cells is mediated by CD40-CD40L interactions and is potentiated by IL-4 and inhibited by both IL-10 and IL-21. These findings appear physiologically relevant because CD4 T cell expression of CD40L correlated with the frequency of CD32B low/neg cells in the CD27(+)IgD(-) memory B subset in patients with RA. Our data support a model in which high levels of CD40L, present on circulating T cells in patients with RA, causes B cell activation and CD32B downregulation, resulting in secondary protection of memory B cells from CD32B-mediated cell death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686494     DOI: 10.4049/jimmunol.1203366

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  NF-κB and Rheumatoid Arthritis: Will Understanding Genetic Risk Lead to a Therapeutic Reward?

Authors:  Robert Scheinman
Journal:  For Immunopathol Dis Therap       Date:  2013-04-01

2.  Immunization associated with erectile dysfunction based on cross-sectional and genetic analyses.

Authors:  Yang Chen; Xianxiang Xin; Haiying Zhang; Jianfeng Xu; Yong Gao; Aihua Tan; Xiaobo Yang; Xue Qin; Yanling Hu; Zengnan Mo
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

3.  A Transmembrane Polymorphism of Fcγ Receptor IIb Is Associated with Kidney Deficiency Syndrome in Rheumatoid Arthritis.

Authors:  Na Mo; Ruogu Lai; Shizi Luo; Jianglin Xie; Xizi Wang; Lijuan Liu; Xiaoling Liu; Guangxing Chen
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-08       Impact factor: 2.629

4.  Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Wayne B Dyer; Joanne C G Tan; Timothy Day; Lynette Kiers; Matthew C Kiernan; Con Yiannikas; Stephen Reddel; Karl Ng; Phillip Mondy; Peta M Dennington; Melinda M Dean; Halina M Trist; Cristobal Dos Remedios; P Mark Hogarth; Steve Vucic; David O Irving
Journal:  Brain Behav       Date:  2016-07-14       Impact factor: 2.708

5.  FcγRIIb Expression Is Decreased on Naive and Marginal Zone-Like B Cells From Females With Multiple Sclerosis.

Authors:  Stephanie Trend; Jonatan Leffler; Ingrid Teige; Björn Frendéus; Allan G Kermode; Martyn A French; Prue H Hart
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

Review 6.  Apoptosis, Autophagy, NETosis, Necroptosis, and Pyroptosis Mediated Programmed Cell Death as Targets for Innovative Therapy in Rheumatoid Arthritis.

Authors:  Jianan Zhao; Ping Jiang; Shicheng Guo; Steven J Schrodi; Dongyi He
Journal:  Front Immunol       Date:  2021-12-24       Impact factor: 7.561

7.  Synovial IL-9 facilitates neutrophil survival, function and differentiation of Th17 cells in rheumatoid arthritis.

Authors:  Kaustav Chowdhury; Uma Kumar; Soumabha Das; Jaydeep Chaudhuri; Prabin Kumar; Maumita Kanjilal; Parashar Ghosh; Geetabali Sircar; Ravi Kiran Basyal; Uma Kanga; Santu Bandyopadhaya; Dipendra Kumar Mitra
Journal:  Arthritis Res Ther       Date:  2018-01-30       Impact factor: 5.156

8.  Increased Expression of TLR10 in B Cell Subsets Correlates with Disease Activity in Rheumatoid Arthritis.

Authors:  Ying Zhang; Rong Cao; Haijian Ying; Juping Du; Shuaishuai Chen; Na Wang; Bo Shen
Journal:  Mediators Inflamm       Date:  2018-12-27       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.